Skip to main content

Tissue inhibitor of metalloproteinases (TIMPs) in heart failure

Heart Failure Reviews volume 17, pages 693–706 (2012)Cite this article

Abstract

Remodeling of the myocardium and the extracellular matrix (ECM) occurs in heart failure irrespective of its initial cause. The ECM serves as a scaffold to provide structural support as well as housing a number of cytokines and growth factors. Hence, disruption of the ECM will result in structural instability as well as activation of a number of signaling pathways that could lead to fibrosis, hypertrophy, and apoptosis. The ECM is a dynamic entity that undergoes constant turnover, and the integrity of its network structure is maintained by a balance in the function of matrix metalloproteinases (MMPs) and their inhibitors, the tissue inhibitor of metalloproteinases (TIMPs). In heart disease, levels of MMPs and TIMPs are altered resulting in an imbalance between these two families of proteins. In this review, we will discuss the structure, function, and regulation of TIMPs, their MMP-independent functions, and their role in heart failure. We will review the knowledge that we have gained from clinical studies and animal models on the contribution of TIMPs in the development and progression of heart disease. We will further discuss how ECM molecules and regulatory genes can be used as biomarkers of disease in heart failure patients.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1

Abbreviations

ADAM:

A disintegrin and matrix metalloproteinase

CITP:

Carboxy-terminal telopeptide of collagen type I

DCM:

Dilated cardiomyopathy

ECM:

Extracellular Matrix

FGF:

Fibroblast growth factor

HB-EGF:

Heparin-bound epidermal growth factor

IL:

Interleukin

LV:

Left ventricle

MI:

Myocardial infarction

MMP:

Matrix metalloproteinase

MT-MMP:

Membrane-type MMP

PDGF:

Platelet-derived growth factor

PICP:

Procollagen type I carboxy-terminal propeptide

PINP:

Procollagen type I amino-terminal propeptides

PIIINP:

Procollagen type III amino-terminal pro-peptide

TIMP:

Tissue inhibitor metalloproteinase

TGFβ:

Transforming growth factor-beta

TNFα:

Tumor necrosis factor-alpha

VEGF:

Vascular endothelial growth factor

WT:

Wild-type

References

  1. Hunt SA, Abraham WT, Chin MH et al (2005) ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112:e154–e235

    PubMed  Google Scholar 

  2. Li YY, McTiernan CF, Feldman AM (2000) Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 46:214–224

    PubMed  CAS  Google Scholar 

  3. Spinale FG (2007) Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 87:1285–1342

    PubMed  CAS  Google Scholar 

  4. Spinale FG, Wilbur NM (2009) Matrix metalloproteinase therapy in heart failure. Curr Treat Options Cardiovasc Med 11:339–346

    PubMed  Google Scholar 

  5. Ross RS, Borg TK (2001) Integrins and the myocardium. Circ Res 88:1112–1119

    PubMed  CAS  Google Scholar 

  6. Manso AM, Elsherif L, Kang SM et al (2006) Integrins, membrane-type matrix metalloproteinases and ADAMs: potential implications for cardiac remodeling. Cardiovasc Res 69:574–584

    PubMed  CAS  Google Scholar 

  7. Carver W, Molano I, Reaves TA et al (1995) Role of the alpha 1 beta 1 integrin complex in collagen gel contraction in vitro by fibroblasts. J Cell Physiol 165:425–437

    PubMed  CAS  Google Scholar 

  8. Hyytiainen M, Penttinen C, Keski-Oja J (2004) Latent TGF-beta binding proteins: extracellular matrix association and roles in TGF-beta activation. Crit Rev Clin Lab Sci 41:233–264

    PubMed  Google Scholar 

  9. Mann DL, Spinale FG (1998) Activation of matrix metalloproteinases in the failing human heart: breaking the tie that binds. Circulation 98:1699–1702

    PubMed  CAS  Google Scholar 

  10. Kelly D, Khan S, Cockerill G et al (2008) Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction. Eur J Heart Fail 10:133–139

    PubMed  CAS  Google Scholar 

  11. Barbolina MV, Stack MS (2008) Membrane type 1-matrix metalloproteinase: substrate diversity in pericellular proteolysis. Semin Cell Dev Biol 19:24–33

    PubMed  CAS  Google Scholar 

  12. Takino T, Saeki H, Miyamori H et al (2007) Inhibition of membrane-type 1 matrix metalloproteinase at cell-matrix adhesions. Cancer Res 67:11621–11629

    PubMed  CAS  Google Scholar 

  13. Shen XM, Wu YP, Feng YB et al (2007) Interaction of MT1-MMP and laminin-5gamma2 chain correlates with metastasis and invasiveness in human esophageal squamous cell carcinoma. Clin Exp Metastasis 24:541–550

    PubMed  CAS  Google Scholar 

  14. Steffensen B, Wallon UM, Overall CM (1995) Extracellular matrix binding properties of recombinant fibronectin type II-like modules of human 72-kDa gelatinase/type IV collagenase. High affinity binding to native type I collagen but not native type IV collagen. J Biol Chem 270:11555–11566

    PubMed  CAS  Google Scholar 

  15. Vincenti MP, Coon CI, Mengshol JA et al (1998) Cloning of the gene for interstitial collagenase-3 (matrix metalloproteinase-13) from rabbit synovial fibroblasts: differential expression with collagenase-1 (matrix metalloproteinase-1). Biochem J 331(Pt 1):341–346

    PubMed  CAS  Google Scholar 

  16. Nuttall RK, Sampieri CL, Pennington CJ et al (2004) Expression analysis of the entire MMP and TIMP gene families during mouse tissue development. FEBS Lett 563:129–134

    PubMed  CAS  Google Scholar 

  17. Baker AH, Edwards DR, Murphy G (2002) Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 115:3719–3727

    PubMed  CAS  Google Scholar 

  18. Melendez-Zajgla J, Del Pozo L, Ceballos G et al. (2008) Tissue inhibitor of metalloproteinases-4. The road less traveled. Mol Cancer 7:85

    Google Scholar 

  19. Santos-Martinez MJ, Medina C, Jurasz P et al (2008) Role of metalloproteinases in platelet function. Thromb Res 121:535–542

    PubMed  CAS  Google Scholar 

  20. Sottrup-Jensen L, Birkedal-Hansen H (1989) Human fibroblast collagenase-alpha-macroglobulin interactions. Localization of cleavage sites in the bait regions of five mammalian alpha-macroglobulins. J Biol Chem 264:393–401

    PubMed  CAS  Google Scholar 

  21. Oh J, Takahashi R, Kondo S et al (2001) The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 107:789–800

    PubMed  CAS  Google Scholar 

  22. Oh J, Seo DW, Diaz T et al (2004) Tissue inhibitors of metalloproteinase 2 inhibits endothelial cell migration through increased expression of RECK. Cancer Res 64:9062–9069

    PubMed  CAS  Google Scholar 

  23. Tuuttila A, Morgunova E, Bergmann U et al (1998) Three-dimensional structure of human tissue inhibitor of metalloproteinases-2 at 2.1 A resolution. J Mol Biol 284:1133–1140

    PubMed  CAS  Google Scholar 

  24. Douglas DA, Shi YE, Sang QA (1997) Computational sequence analysis of the tissue inhibitor of metalloproteinase family. J Protein Chem 16:237–255

    PubMed  CAS  Google Scholar 

  25. Apte SS, Olsen BR, Murphy G (1995) The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. J Biol Chem 270:14313–14318

    PubMed  CAS  Google Scholar 

  26. Langton KP, Barker MD, McKie N (1998) Localization of the functional domains of human tissue inhibitor of metalloproteinases-3 and the effects of a Sorsby’s fundus dystrophy mutation. J Biol Chem 273:16778–16781

    PubMed  CAS  Google Scholar 

  27. Caterina NC, Windsor LJ, Bodden MK et al (1998) Glycosylation and NH2-terminal domain mutants of the tissue inhibitor of metalloproteinases-1 (TIMP-1). Biochim Biophys Acta 1388:21–34

    PubMed  CAS  Google Scholar 

  28. Dennis JW, Granovsky M, Warren CE (1999) Protein glycosylation in development and disease. Bioessays 21:412–421

    PubMed  CAS  Google Scholar 

  29. Stroud RE, Deschamps AM, Lowry AS et al (2005) Plasma monitoring of the myocardial specific tissue inhibitor of metalloproteinase-4 after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. J Card Fail 11:124–130

    PubMed  CAS  Google Scholar 

  30. Gomez DE, Alonso DF, Yoshiji H et al (1997) Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 74:111–122

    PubMed  CAS  Google Scholar 

  31. Birkedal-Hansen H, Moore WG, Bodden MK et al (1993) Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 4:197–250

    PubMed  CAS  Google Scholar 

  32. Lambert E, Dasse E, Haye B et al (2004) TIMPs as multifacial proteins. Crit Rev Oncol Hematol 49:187–198

    PubMed  Google Scholar 

  33. Strongin AY, Collier I, Bannikov G et al (1995) Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 270:5331–5338

    PubMed  CAS  Google Scholar 

  34. Atkinson SJ, Crabbe T, Cowell S et al (1995) Intermolecular autolytic cleavage can contribute to the activation of progelatinase A by cell membranes. J Biol Chem 270:30479–30485

    PubMed  CAS  Google Scholar 

  35. Bigg HF, Morrison CJ, Butler GS et al (2001) Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase. Cancer Res 61:3610–3618

    PubMed  CAS  Google Scholar 

  36. English JL, Kassiri Z, Koskivirta I et al (2006) Individual Timp deficiencies differentially impact pro-MMP-2 activation. J Biol Chem 281:10337–10346

    PubMed  CAS  Google Scholar 

  37. Liu YE, Wang M, Greene J et al (1997) Preparation and characterization of recombinant tissue inhibitor of metalloproteinase 4 (TIMP-4). J Biol Chem 272:20479–20483

    PubMed  CAS  Google Scholar 

  38. Kandalam V, Basu R, Abraham T et al (2010) TIMP2 deficiency accelerates adverse post-myocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation. Circ Res 106:796–808

    PubMed  CAS  Google Scholar 

  39. Hernandez-Barrantes S, Shimura Y, Soloway PD et al (2001) Differential roles of TIMP-4 and TIMP-2 in pro-MMP-2 activation by MT1-MMP. Biochem Biophys Res Commun 281:126–130

    PubMed  CAS  Google Scholar 

  40. Kashiwagi M, Tortorella M, Nagase H et al (2001) TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J Biol Chem 276:12501–12504

    PubMed  CAS  Google Scholar 

  41. Brew K, Nagase H (2010) The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta 1803:55–71

    PubMed  CAS  Google Scholar 

  42. Loechel F, Fox JW, Murphy G et al (2000) ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem Biophys Res Commun 278:511–515

    PubMed  CAS  Google Scholar 

  43. Wisniewska M, Goettig P, Maskos K et al (2008) Structural determinants of the ADAM inhibition by TIMP-3: crystal structure of the TACE-N-TIMP-3 complex. J Mol Biol 381:1307–1319

    PubMed  CAS  Google Scholar 

  44. Amour A, Slocombe PM, Webster A et al (1998) TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett 435:39–44

    PubMed  CAS  Google Scholar 

  45. Asakura M, Kitakaze M, Takashima S et al (2002) Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 8:35–40

    PubMed  CAS  Google Scholar 

  46. Black RA, Rauch CT, Kozlosky CJ et al (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385:729–733

    PubMed  CAS  Google Scholar 

  47. Lee DC, Sunnarborg SW, Hinkle CL et al (2003) TACE/ADAM17 processing of EGFR ligands indicates a role as a physiological convertase. Ann N Y Acad Sci 995:22–38

    PubMed  CAS  Google Scholar 

  48. Kassiri Z, Oudit GY, Sanchez O et al (2005) Combination of tumor necrosis factor-alpha ablation and matrix metalloproteinase inhibition prevents heart failure after pressure overload in tissue inhibitor of metalloproteinase-3 knock-out mice. Circ Res 97:380–390

    PubMed  CAS  Google Scholar 

  49. Smookler DS, Mohammed FF, Kassiri Z et al (2006) Tissue inhibitor of metalloproteinase 3 regulates TNF-dependent systemic inflammation. J Immunol 176:721–725

    PubMed  CAS  Google Scholar 

  50. Kassiri Z, Oudit GY, Kandalam V et al (2009) Loss of TIMP3 enhances interstitial nephritis and fibrosis. J Am Soc Nephrol 20:1223–1235

    PubMed  CAS  Google Scholar 

  51. Clark IM, Swingler TE, Sampieri CL et al (2008) The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 40:1362–1378

    PubMed  CAS  Google Scholar 

  52. Yu WH, Yu S, Meng Q et al (2000) TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. J Biol Chem 275:31226–31232

    PubMed  CAS  Google Scholar 

  53. Schulze CJ, Wang W, Suarez-Pinzon WL et al (2003) Imbalance between tissue inhibitor of metalloproteinase-4 and matrix metalloproteinases during acute myocardial ischemia-reperfusion injury. Circulation 107:2487–2492

    PubMed  CAS  Google Scholar 

  54. Kadri Z, Petitfrere E, Boudot C et al (2000) Erythropoietin induction of tissue inhibitors of metalloproteinase-1 expression and secretion is mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways. Cell Growth Differ 11:573–580

    PubMed  CAS  Google Scholar 

  55. Li WQ, Qureshi HY, Liacini A et al (2004) Transforming growth factor Beta1 induction of tissue inhibitor of metalloproteinases 3 in articular chondrocytes is mediated by reactive oxygen species. Free Radic Biol Med 37:196–207

    PubMed  Google Scholar 

  56. Hoshino Y, Mio T, Nagai S et al (2001) Fibrogenic and inflammatory cytokines modulate mRNA expressions of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-3 in type II pneumocytes. Respiration 68:509–516

    PubMed  CAS  Google Scholar 

  57. Heymans S, Schroen B, Vermeersch P et al (2005) Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation 112:1136–1144

    PubMed  CAS  Google Scholar 

  58. Fielitz J, Leuschner M, Zurbrugg HR et al (2004) Regulation of matrix metalloproteinases and their inhibitors in the left ventricular myocardium of patients with aortic stenosis. J Mol Med 82:809–820

    PubMed  CAS  Google Scholar 

  59. Polyakova V, Miyagawa S, Szalay Z et al (2008) Atrial extracellular matrix remodelling in patients with atrial fibrillation. J Cell Mol Med 12:189–208

    PubMed  CAS  Google Scholar 

  60. Kim H, Oda T, Lopez-Guisa J et al (2001) TIMP-1 deficiency does not attenuate interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 12:736–748

    PubMed  CAS  Google Scholar 

  61. Kassiri Z, Oudit G, Kandalam V et al. (2009) Loss of TIMP3 enhances TNFα and matrix metalloproteinase-mediated interstitial nephritis. J Am Assoc Nephrol (accepted)

  62. Zhong ZD, Hammani K, Bae WS et al (2000) NF-Y and Sp1 cooperate for the transcriptional activation and cAMP response of human tissue inhibitor of metalloproteinases-2. J Biol Chem 275:18602–18610

    PubMed  CAS  Google Scholar 

  63. Tanaka K, Iwamoto Y, Ito Y et al (1995) Cyclic AMP-regulated synthesis of the tissue inhibitors of metalloproteinases suppresses the invasive potential of the human fibrosarcoma cell line HT1080. Cancer Res 55:2927–2935

    PubMed  CAS  Google Scholar 

  64. Buzzio OL, Lu Z, Miller CD et al (2006) FOXO1A differentially regulates genes of decidualization. Endocrinology 147:3870–3876

    PubMed  CAS  Google Scholar 

  65. Clark IM, Rowan AD, Edwards DR et al (1997) Transcriptional activity of the human tissue inhibitor of metalloproteinases 1 (TIMP-1) gene in fibroblasts involves elements in the promoter, exon 1 and intron 1. Biochem J 324(Pt 2):611–617

    PubMed  CAS  Google Scholar 

  66. Hammani K, Blakis A, Morsette D et al (1996) Structure and characterization of the human tissue inhibitor of metalloproteinases-2 gene. J Biol Chem 271:25498–25505

    PubMed  CAS  Google Scholar 

  67. Sun Y, Hegamyer G, Kim H et al (1995) Molecular cloning of mouse tissue inhibitor of metalloproteinases-3 and its promoter. Specific lack of expression in neoplastic JB6 cells may reflect altered gene methylation. J Biol Chem 270:19312–19319

    PubMed  CAS  Google Scholar 

  68. Young DA, Phillips BW, Lundy C et al (2002) Identification of an initiator-like element essential for the expression of the tissue inhibitor of metalloproteinases-4 (Timp-4) gene. Biochem J 364:89–99

    PubMed  CAS  Google Scholar 

  69. Zamore PD, Haley B (2005) Ribo-gnome: the big world of small RNAs. Science 309:1519–1524

    PubMed  CAS  Google Scholar 

  70. Ambros V (2004) The functions of animal microRNAs. Nature 431:350–355

    PubMed  CAS  Google Scholar 

  71. Garofalo M, Di Leva G, Romano G et al (2009) miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 16:498–509

    PubMed  CAS  Google Scholar 

  72. Song B, Wang C, Liu J et al. (2010) MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. J Exp Clin Cancer Res 29:29

    Google Scholar 

  73. Liu H, Chen SE, Jin B et al (2010) TIMP3: a physiological regulator of adult myogenesis. J Cell Sci 123:2914–2921

    PubMed  CAS  Google Scholar 

  74. Kassiri Z, Khokha R (2005) Myocardial extra-cellular matrix and its regulation by metalloproteinases and their inhibitors. Thromb Haemost 93:212–219

    PubMed  CAS  Google Scholar 

  75. Zannad F, Rossignol P, Iraqi W (2010) Extracellular matrix fibrotic markers in heart failure. Heart Fail Rev 15:319–329

    PubMed  CAS  Google Scholar 

  76. Martos R, Baugh J, Ledwidge M et al (2009) Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover. Eur J Heart Fail 11:191–197

    PubMed  CAS  Google Scholar 

  77. Diez J, Querejeta R, Lopez B et al (2002) Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105:2512–2517

    PubMed  CAS  Google Scholar 

  78. Izawa H, Murohara T, Nagata K et al (2005) Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation 112:2940–2945

    PubMed  CAS  Google Scholar 

  79. Poulsen SH, Host NB, Jensen SE et al (2000) Relationship between serum amino-terminal propeptide of type III procollagen and changes of left ventricular function after acute myocardial infarction. Circulation 101:1527–1532

    PubMed  CAS  Google Scholar 

  80. Manhenke C, Orn S, Squire I et al. (2010) The prognostic value of circulating markers of collagen turnover after acute myocardial infarction. Int J Cardiol (Epub ahead of print May 2010)

  81. Jugdutt BI, Joljart MJ, Khan MI (1996) Rate of collagen deposition during healing and ventricular remodeling after myocardial infarction in rat and dog models. Circulation 94:94–101

    PubMed  CAS  Google Scholar 

  82. Webb CS, Bonnema DD, Ahmed SH et al (2006) Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation 114:1020–1027

    PubMed  CAS  Google Scholar 

  83. Pouleur AC, Barkoudah E, Uno H et al (2010) Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. Circulation 122:597–602

    PubMed  Google Scholar 

  84. Jugdutt BI (2010) Preventing adverse remodeling and rupture during healing after myocardial infarction in mice and humans. Circulation 122:103–105

    PubMed  Google Scholar 

  85. Kandalam V, Basu R, Abraham T et al (2010) Early activation of matrix metalloproteinases underlies the exacerbated systolic and diastolic dysfunction in mice lacking TIMP3 following myocardial infarction. Am J Physiol Heart Circ Physiol 299:H1012–H1023

    PubMed  CAS  Google Scholar 

  86. Yang Y, Ma Y, Han W et al (2008) Age-related differences in postinfarct left ventricular rupture and remodeling. Am J Physiol Heart Circ Physiol 294:H1815–H1822

    PubMed  CAS  Google Scholar 

  87. Kelly D, Khan SQ, Thompson M et al (2008) Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. Eur Heart J 29:2116–2124

    PubMed  Google Scholar 

  88. Kelly D, Squire IB, Khan SQ et al (2010) Usefulness of plasma tissue inhibitors of metalloproteinases as markers of prognosis after acute myocardial infarction. Am J Cardiol 106:477–482

    PubMed  CAS  Google Scholar 

  89. Li YY, Feldman AM, Sun Y et al (1998) Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 98:1728–1734

    PubMed  CAS  Google Scholar 

  90. Tummalapalli CM, Heath BJ, Tyagi SC (2001) Tissue inhibitor of metalloproteinase-4 instigates apoptosis in transformed cardiac fibroblasts. J Cell Biochem 80:512–521

    PubMed  CAS  Google Scholar 

  91. Thomas CV, Coker ML, Zellner JL et al (1998) Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 97:1708–1715

    PubMed  CAS  Google Scholar 

  92. Li YY, Feng Y, McTiernan CF et al (2001) Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Circulation 104:1147–1152

    PubMed  CAS  Google Scholar 

  93. Noji Y, Shimizu M, Ino H et al (2004) Increased circulating matrix metalloproteinase-2 in patients with hypertrophic cardiomyopathy with systolic dysfunction. Circ J 68:355–360

    PubMed  CAS  Google Scholar 

  94. Timms PM, Wright A, Maxwell P et al (2002) Plasma tissue inhibitor of metalloproteinase-1 levels are elevated in essential hypertension and related to left ventricular hypertrophy. Am J Hypertens 15:269–272

    PubMed  CAS  Google Scholar 

  95. Lindsay MM, Maxwell P, Dunn FG (2002) TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 40:136–141

    PubMed  CAS  Google Scholar 

  96. Mukherjee R, Herron AR, Lowry AS et al (2006) Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol 97:532–537

    PubMed  CAS  Google Scholar 

  97. Biolo A, Ramamurthy S, LConnors LH et al (2008) Matrix Metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition. Circulat Heart Failure 1:249–257

    CAS  Google Scholar 

  98. Barton PJ, Birks EJ, Felkin LE et al (2003) Increased expression of extracellular matrix regulators TIMP1 and MMP1 in deteriorating heart failure. J Heart Lung Transplant 22:738–744

    PubMed  Google Scholar 

  99. Tyagi SC, Kumar S, Voelker DJ et al (1996) Differential gene expression of extracellular matrix components in dilated cardiomyopathy. J Cell Biochem 63:185–198

    PubMed  CAS  Google Scholar 

  100. Sundstrom J, Evans JC, Benjamin EJ et al (2004) Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study. Eur Heart J 25:1509–1516

    PubMed  CAS  Google Scholar 

  101. Gonzalez A, Lopez B, Querejeta R et al (2010) Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction. Hypertension 55:1418–1424

    PubMed  CAS  Google Scholar 

  102. Zile MR, Desantis SM, Baicu CF et al. (2011) Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail 4(3):246–256

    Google Scholar 

  103. Iwanaga Y, Aoyama T, Kihara Y et al (2002) Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats. J Am Coll Cardiol 39:1384–1391

    PubMed  CAS  Google Scholar 

  104. Gill SE, Kassim SY, Birkland TP et al (2010) Mouse models of MMP and TIMP function. Methods Mol Biol 622:31–52

    PubMed  CAS  Google Scholar 

  105. Roten L, Nemoto S, Simsic J et al (2000) Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice. J Mol Cell Cardiol 32:109–120

    PubMed  CAS  Google Scholar 

  106. Creemers EE, Davis JN, Parkhurst AM et al (2003) Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol 284:H364–H371

    PubMed  CAS  Google Scholar 

  107. Ikonomidis JS, Hendrick JW, Parkhurst AM et al (2005) Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition. Am J Physiol Heart Circ Physiol 288:H149–H158

    PubMed  CAS  Google Scholar 

  108. Wang Z, Juttermann R, Soloway PD (2000) TIMP-2 is required for efficient activation of proMMP-2 in vivo. J Biol Chem 275:26411–26415

    PubMed  CAS  Google Scholar 

  109. Kandalam V, Basu R, Moore L et al. (2011) Lack of TIMP2 leads to exacerbated LV dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress. Circulation Resubmitted (minor Revisions)

  110. Ramani R, Nilles K, Gibson G et al (2011) Tissue inhibitor of metalloproteinase-2 gene delivery ameliorates postinfarction cardiac remodeling. Clin Transl Sci 4:24–31

    PubMed  CAS  Google Scholar 

  111. Fedak PW, Smookler DS, Kassiri Z et al (2004) TIMP-3 deficiency leads to dilated cardiomyopathy. Circulation 110:2401–2409

    PubMed  CAS  Google Scholar 

  112. Kassiri Z, Defamie V, Hariri M et al. (2009) Simultaneous TGFbeta-TNF activation and cross-talk cause aberrant remodeling response and myocardial fibrosis in tissue inhibitor of metalloproteinase 3 deficient heart. J Biol Chem 284(43):29893–29904

    Google Scholar 

  113. Tian H, Cimini M, Fedak PW et al (2007) TIMP-3 deficiency accelerates cardiac remodeling after myocardial infarction. J Mol Cell Cardiol 43:733–743

    PubMed  CAS  Google Scholar 

  114. Koskivirta I, Kassiri Z, Rahkonen O et al. (2010) Mice with tissue inhibitor of metalloproteinases 4 (Timp4) deletion succumb to induced myocardial infarction but not to cardiac pressure overload. J Biol Chem 285:24487–24493

    Google Scholar 

  115. Takahashi T, Hiasa Y, Ohara Y et al (2008) Relationship of admission neutrophil count to microvascular injury, left ventricular dilation, and long-term outcome in patients treated with primary angioplasty for acute myocardial infarction. Circ J 72:867–872

    PubMed  Google Scholar 

  116. Papa A, Emdin M, Passino C et al. (2008) Predictive value of elevated neutrophil-lymphocyte ratio on cardiac mortality in patients with stable coronary artery disease. Clin Chim Acta 395(1–2):27–31

    Google Scholar 

  117. Koskivirta I, Kassiri Z, Rahkonen O et al (2010) Mice with tissue inhibitor of metalloproteinases 4 (Timp4) deletion succumb to induced myocardial infarction but not to cardiac pressure overload. J Biol Chem 285:24487–24493

    PubMed  CAS  Google Scholar 

  118. Doherty DE, Henson PM, Clark RA (1990) Fibronectin fragments containing the RGDS cell-binding domain mediate monocyte migration into the rabbit lung. A potential mechanism for C5 fragment-induced monocyte lung accumulation. J Clin Invest 86:1065–1075

    PubMed  CAS  Google Scholar 

  119. Senior RM, Griffin GL, Mecham RP (1980) Chemotactic activity of elastin-derived peptides. J Clin Invest 66:859–862

    PubMed  CAS  Google Scholar 

  120. Matsumura S, Iwanaga S, Mochizuki S et al (2005) Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J Clin Invest 115:599–609

    PubMed  CAS  Google Scholar 

  121. Adair-Kirk TL, Senior RM (2008) Fragments of extracellular matrix as mediators of inflammation. Int J Biochem Cell Biol 40:1101–1110

    PubMed  CAS  Google Scholar 

  122. Clark RA, Wikner NE, Doherty DE et al (1988) Cryptic chemotactic activity of fibronectin for human monocytes resides in the 120-kDa fibroblastic cell-binding fragment. J Biol Chem 263:12115–12123

    PubMed  CAS  Google Scholar 

  123. Hance KA, Tataria M, Ziporin SJ et al (2002) Monocyte chemotactic activity in human abdominal aortic aneurysms: role of elastin degradation peptides and the 67-kD cell surface elastin receptor. J Vasc Surg 35:254–261

    PubMed  Google Scholar 

  124. Van Lint P, Libert C (2006) Matrix metalloproteinase-8: cleavage can be decisive. Cytokine Growth Factor Rev 17:217–223

    PubMed  Google Scholar 

  125. Cuadrado E, Ortega L, Hernandez-Guillamon M et al. (2008) Tissue plasminogen activator (t-PA) promotes neutrophil degranulation and MMP-9 release. J Leukoc Biol 84(1):207–214

    Google Scholar 

  126. Matsuda A, Itoh Y, Koshikawa N et al (2003) Clusterin, an abundant serum factor, is a possible negative regulator of MT6-MMP/MMP-25 produced by neutrophils. J Biol Chem 278:36350–36357

    PubMed  CAS  Google Scholar 

  127. Lambert JM, Lopez EF, Lindsey ML (2008) Macrophage roles following myocardial infarction. Int J Cardiol 130:147–158

    PubMed  Google Scholar 

  128. Gill SE, Huizar I, Bench EM et al (2010) Tissue inhibitor of metalloproteinases 3 regulates resolution of inflammation following acute lung injury. Am J Pathol 176:64–73

    PubMed  CAS  Google Scholar 

  129. Vanhoutte D, Heymans S (2010) TIMPs and cardiac remodeling: ‘embracing the MMP-independent-side of the family’. J Mol Cell Cardiol 48:445–453

    PubMed  CAS  Google Scholar 

  130. Chirco R, Liu XW, Jung KK et al (2006) Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 25:99–113

    PubMed  CAS  Google Scholar 

  131. Seo DW, Li H, Guedez L et al (2003) TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 114:171–180

    PubMed  CAS  Google Scholar 

  132. Stetler-Stevenson WG, Seo DW (2005) TIMP-2: an endogenous inhibitor of angiogenesis. Trends Mol Med 11:97–103

    PubMed  CAS  Google Scholar 

  133. Lluri G, Langlois GD, McClellan B et al (2006) Tissue inhibitor of metalloproteinase-2 (TIMP-2) regulates neuromuscular junction development via a beta1 integrin-mediated mechanism. J Neurobiol 66:1365–1377

    PubMed  CAS  Google Scholar 

  134. Qi JH, Ebrahem Q, Moore N et al (2003) A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 9:407–415

    PubMed  CAS  Google Scholar 

  135. Mohammed FF, Smookler DS, Taylor SE et al (2004) Abnormal TNF activity in Timp3−/− mice leads to chronic hepatic inflammation and failure of liver regeneration. Nat Genet 36:969–977

    PubMed  CAS  Google Scholar 

  136. Lovelock JD, Baker AH, Gao F et al (2005) Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. Am J Physiol Heart Circ Physiol 288:H461–H468

    PubMed  CAS  Google Scholar 

  137. Hayakawa T, Yamashita K, Tanzawa K et al (1992) Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 298:29–32

    PubMed  CAS  Google Scholar 

  138. Corcoran ML, Stetler-Stevenson WG (1995) Tissue inhibitor of metalloproteinase-2 stimulates fibroblast proliferation via a cAMP-dependent mechanism. J Biol Chem 270:13453–13459

    PubMed  CAS  Google Scholar 

  139. Murphy AN, Unsworth EJ, Stetler-Stevenson WG (1993) Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 157:351–358

    PubMed  CAS  Google Scholar 

  140. Wingfield PT, Sax JK, Stahl SJ et al (1999) Biophysical and functional characterization of full-length, recombinant human tissue inhibitor of metalloproteinases-2 (TIMP-2) produced in Escherichia coli. Comparison of wild type and amino-terminal alanine appended variant with implications for the mechanism of TIMP functions. J Biol Chem 274:21362–21368

    PubMed  CAS  Google Scholar 

  141. Yang TT, Hawkes SP (1992) Role of the 21-kDa protein TIMP-3 in oncogenic transformation of cultured chicken embryo fibroblasts. Proc Natl Acad Sci USA 89:10676–10680

    PubMed  CAS  Google Scholar 

  142. Hammoud L, Xiang F, Lu X et al (2007) Endothelial nitric oxide synthase promotes neonatal cardiomyocyte proliferation by inhibiting tissue inhibitor of metalloproteinase-3 expression. Cardiovasc Res 75:359–368

    PubMed  CAS  Google Scholar 

  143. Celiker MY, Wang M, Atsidaftos E et al (2001) Inhibition of Wilms’ tumor growth by intramuscular administration of tissue inhibitor of metalloproteinases-4 plasmid DNA. Oncogene 20:4337–4343

    PubMed  CAS  Google Scholar 

  144. Zamilpa R, Lindsey ML (2010) Extracellular matrix turnover and signaling during cardiac remodeling following MI: causes and consequences. J Mol Cell Cardiol 48:558–563

    PubMed  CAS  Google Scholar 

  145. Hutchinson KR, Stewart JA Jr, Lucchesi PA (2009) Extracellular matrix remodeling during the progression of volume overload-induced heart failure. J Mol Cell Cardiol 48:564–569

    PubMed  Google Scholar 

  146. Hudson MP, Armstrong PW, Ruzyllo W et al (2006) Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol 48:15–20

    PubMed  CAS  Google Scholar 

  147. Biolo A, Ramamurthy S, Connors LH et al (2008) Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition. Circ Heart Fail 1:249–257

    PubMed  CAS  Google Scholar 

  148. Johnson RR, Hapke E, Hendrick JW et al. (2002) Chronic pressure overload: Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase type 1 (TIMP-1) on hypertrophic remodeling. Abs # 2125. Circulation Suppl 106:II-427

    Google Scholar 

Download references

Acknowledgments

ZK is a New Investigator of Heart and Stroke Foundation of Canada (HSFC) and an Alberta Innovates-Health Solutions (AIHS) Scholar. VK is supported by AIHS studentship, and RB is supported by Motyl Scholarship.

Conflict of interest

L. Moore, V. Kandalam, and Drs. Fan, Basu, and Kassiri have no conflicts of interest or financial ties to disclose.

Author information

Authors and Affiliations

  1. Department of Physiology, Cardiovascular Research Centre, Mazankowski Alberta Heart Institute, University of Alberta, Rm 474, Heritage Medical Research Centre, Edmonton, AB, T6G 2S2, Canada

    Linn Moore, Dong Fan, Ratnadeep Basu, Vijay Kandalam & Zamaneh Kassiri

Authors
  1. Linn Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dong Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ratnadeep Basu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vijay Kandalam
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zamaneh Kassiri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zamaneh Kassiri.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Moore, L., Fan, D., Basu, R. et al. Tissue inhibitor of metalloproteinases (TIMPs) in heart failure. Heart Fail Rev 17, 693–706 (2012). https://doi.org/10.1007/s10741-011-9266-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10741-011-9266-y

Keywords

  • Heart failure
  • Extracellular matrix
  • Remodeling
  • Tissue inhibitor of metalloproteinases
  • Matrix metalloproteinases